INTRODUCTION {#s1}
============

Carcinoma of unknown primary (CUP) remains a unique challenge to the clinician in a landscape where algorithms for the diagnosis, management and outcomes of cancers are often histology-dependent. Indeed, CUP represents a heterogeneous group of malignancies with a distinct disease course and biology, often displaying aggressive behavior with a short period of clinical symptoms preceding diagnosis and early dissemination to multiple metastatic sites leading to advanced staging at presentation and \[[@R1]--[@R3]\]. CUP is defined as a metastatic cancer without a clearly identified primary site despite an adequate standard workup including an in-depth pathologic analysis with concurrent detailed history, physical examination, and laboratory and radiologic assessments \[[@R4]\].

The preliminary categorization on microscopic evaluation classifi an overarching histology as adenocarcinomas (ranging from well, moderate, poor, or undifferentiated), which represent up to 90% of CUP cases; lesser prevalent characterizations include squamous cell carcinomas, undifferentiated neoplasm, melanoma, sarcoma, or lymphoma seen in the remaining 10% of cases \[[@R5], [@R6]\]. Next, after identification of preliminary histology, the pathologic evaluation continues with a systematic immunohistochemistry algorithm to identify the general cellular subset, including adenocarcinoma, neuroendocrine, germ-cell, etc. while a further testing based on cytokeratins (CKs) may reveal the detailed phenotypic expression of specifi organ \[[@R1]\].

Progress in gene expression and molecular profiling further aids the sub-classification of the tissue of origin into predominant subtypes of cancer, such as gastrointestinal, gynecologic, etc \[[@R7]--[@R10]\]. However, the final definitive histologic identity of the cancer remains elusive. Recent rapid advances in genomic profiling present new opportunities to not only characterize CUP but also offer insight into pathways and cellular systems with aberrations that may be of value as a therapeutic target. To that end, we performed next generation sequencing on patients with advanced, relapsed CUP referred to our phase I clinical trials program to identify potentially future targets for drug development and clinical trial design.

RESULTS {#s2}
=======

Patients characteristics {#s2_1}
------------------------

We identifi 17 consecutive patients with advanced, relapsed CUP on whom adequate tissue was available for molecular profi Patient characteristics are described in Table [1](#T1){ref-type="table"}. The median age of this group at the time of diagnosis was 49 years (range, 18-72), while the age at time of initial phase I referral was 54 years (range, 21-75). Patients had a preserved performance status with all having an ECOG PS of 0 (n=2, 12%) or 1 (n=15, 88%). Patients were heavily pretreated with the median number of prior systemic therapies prior to phase I referral being 3 (range, 0-8). On pathologic evaluation, fi of 17 patients (29%) had tumor with a microscopic description of carcinoma, 4 of which was poorly differentiated and one undifferentiated. Four patients\' tumors (24%) were characterized as adenocarcinoma, 3 of which were poorly- and one moderately differentiated. Three patients had a squamous cell of unknown primary (two moderately differentiated and one poorly differentiated). Remaining histologies described included moderate to well-differentiated epithelioid neoplasm (n=2, 12%), poorly differentiated neuroendocrine (n=2, 12%), and poorly differentiated sarcomatoid neoplasm (n=1, 6%).

###### Characteristics of 17 patients with advanced relapsed CUP seen in the Phase I Clinical Trials Program

  --------------------------------- ----------
  Gender                            
   Male                             9 (53%)
   Female                           8 (47%)
  Age at diagnosis, years           
   Median                           49
   Range                            18 -- 72
  Age at phase I referral, years    
   Median                           54
   Range                            21-75
  ECOG performance status           
   0                                2 (12%)
   1                                15 (88%)
   2-3                              0
  No. of prior systemic therapies   
   Median                           3
   Range                            0 - 8
  Number of molecular aberrations   
   Median                           2
   Range                            0 - 8
  --------------------------------- ----------

Abbreviations: ECOG Eastern Cooperative Oncology Group.

Molecular analysis by histologic subtype {#s2_2}
----------------------------------------

Of the 17 patients who had adequate tissue for molecular profiling, 15 patients (88%) had one or more molecular aberrations identified on the NGS assay; two patients (one squamous cell and one neuroendocrine by histology) did not reveal any identifiable aberrations. The 17 specimen harbored a total of 59 alterations with a median of 2 mutations and a range of 0 to 8. Table [2](#T2){ref-type="table"} details the pathways and cellular process implicated by the identified molecular aberrations. Overall, the most common aberrations led to impaired cell cycle arrest with 8 patients demonstrating 21 aberrations, including 3 patients with *CDKN2A/B* loss and 2 with *CCND1* amplification.

###### Cellular processes and pathway with identified aberrations in advanced CUP patients

  Processes and pathways implicated                       Mutations identified in tested specimen
  ------------------------------------------------------- -----------------------------------------------
  Apoptosis                                               MCL1 amplification
  Cell cycle regulation                                   CDKN2A/B loss, SOX2 amplification
  CDK12 Q570\*, CCND1 amplification                       
  FGF19 amplification, FGF3 amplification                 
  FGF4 amplification, CCNE1 amplification                 
  CCND1 amplification, SMARCB1 I365fs\*22+                
  Epigenetic regulation                                   MLL2 R4904\*, KDM6A S466
  ARID1A Y1211fs\*5, S1929fs\*25, and E2250fs\*28         
  SETD2 G1644\*, N2071fs\*17                              
  ATRX R840fs\*29, CREBBP S893L                           
  PI3K/AKT/mTOR pathway signaling                         PIK3CA H1047R, Q75E, E545K, and amplification
  FBXW7 splice 726+1 G\>A, R465H, and W244                
  MAPK pathway signaling                                  KRAS amplification, FGFR1 amplification
  Transcription regulation                                MYCL1 amplification, MYST3 amplification
  EWSR1 EWSR1-CREB1 fusion, EMSY amplification            
  SMAD4 P130S, NFE2L2 D11Y                                
  ETV1 rearrangement, NOTCH1 APIP-NOTCH1 fusion           
  Tumor suppressor                                        MDM4 amplification, MDM2 amplification
  TP53 L45P, Q38fs\*79, R273C, R248Q, R196\*, and R248W   
  Wnt signaling                                           CDC73 Q333\*, CTNNB1 S33P

We then examined the cellular processes and pathways affected within each histologic subtype (detailed in Table [3](#T3){ref-type="table"}) with an emphasis of the two most predominant histology, carcinoma and adenocarcinoma. Of the five patients with a carcinoma, the median number of aberrations was 2 (range 1-8), and the median age at time of phase I evaluation was 65.2 years (range 48.2 -- 74.6). Four of the 5 patients demonstrated an aberration leading to activation of the PI3K/AKT/mTOR pathway, including one patient with a *PIK3CA* Q75E mutation and a second patient with both a *PIK3CA* E545K mutation as well as an amplification. Three of these five carcinoma patients demonstrated a mutation in the tumor suppressor *TP53* (R273C, R248Q, R196\*) while two patients had five aberrations in cell cycle regulation including *CDKN2A/B* loss, and *CCND1* and *CCNE1* amplifications.

###### Mutation profile outcomes by tumor histology

  Histology                          No. of patients   Median age at diagnosis (years)   Cellular Processes Affected (No. of mutations)
  ---------------------------------- ----------------- --------------------------------- ------------------------------------------------
  SCC                                3                 56.5                              PI3K/Akt/mTOR pathway (1)
  RTK (1)                                                                                
  Cell cycle regulation (5)                                                              
  Epigenetic regulation (2)                                                              
  Wnt signaling (1)                                                                      
  Tumor suppressor (1)                                                                   
  Transcription regulation (2)                                                           
  Adenocarcinoma                     4                 67.7                              Apoptosis (1)
  Cell cycle regulation (3)                                                              
  Epigenetic regulation (4)                                                              
  PI3K/Akt/mTOR pathway (1)                                                              
  RTK-EGFR family (1)                                                                    
  RTK; angiogenesis regulation (1)                                                       
  Transcription regulation (4)                                                           
  Tumor suppressor (2)                                                                   
  Sarcomatoid                        1                 24.7                              Transcription regulation
  Neuroendocrine                     2                 19.6                              Cell cycle regulation (4)
  Transcription regulation (1)                                                           
  Tumor suppressor (1)                                                                   
  DNA methylation (1)                                                                    
  Epithelioid                        2                 43.0                              Transcription regulation (2)
  Epigenetic regulation (1)                                                              
  Carcinoma                          5                 49.2                              PI3K/Akt/mTOR pathway (4)
  RAF/MEK/ERK (1)                                                                        
  Cell cycle regulation (5)                                                              
  Tumor suppressor (3)                                                                   
  Wnt signaling (1)                                                                      
  RTK (1)                                                                                

Abbreviations: EGFR epidermal growth factor, RTK receptor tyrosine kinase.

Next, 4 patients had the second predominant histologic subtype of adenocarcinoma. Notably, all 4 patients had an aberration implicated in epigenetic deregulation, specifically in *ARID1A* (Y1211fs\*5 and E2250fs\*28) in two samples, a dual *SETD2* mutation (G1644\*, N2071fs\*17) and a *CREBBP* S893L mutation, highlighting a role in targets cellular epigenetics in therapy. Two mutations including *CDKN2A/B* loss leading to impaired cell cycle regulation were also noted.

Signal transduction mechanisms: Activation of the PI3K and MAPK pathways {#s2_3}
------------------------------------------------------------------------

Overall 8 (47%) patients had an aberration implication in a signal transduction cascade. Specifically 5 patients (29%) had 6 mutations leading to aberrant activation of the PI3k/Akt/mTOR signaling pathways, including three patients with *PIK3CA* mutations, one in the more common site H1047R, and two in less prevalent sites, Q75E and E545K with a concurrent amplification. Three patients had a mutation with *FBXW7* mutation (one splice 726+1 G\>A, a second W244\*, and a third R465H). Three patients (n=3, 18%) had aberrant activation of the MAPK pathway with one patient harboring a KRAS amplification and two with *FGFR1* amplification.

Impaired cell cycle regulation {#s2_4}
------------------------------

Overall, 8 (47%) patients had mutations in cell cycle regulators, most commonly in the cyclin dependent kinases. Three patients (18%) harbored a *CDKN2A/B* loss, both genes encode the tumor suppressors p15 and p16, therefore loss of these genes leads to the deregulation of the p16-CDK4/Cyclin/Rb pathway and loss of cell cycle control \[[@R11]\]. Similarly two patients had a *CCND1* amplification, which encodes Cyclin D1, which in turn interacts with the cyclin-dependent kinases Cdk4 and Cdk6, resulting in the phosphorylation and inactivation of Rb and the progression of the cell cycle. Studies have shown that overexpression or amplification of Cyclin D1 may therefore lead to excessive proliferation \[[@R12], [@R13]\]. Additional aberrations included three (18%) patients with *SOX2* amplification, three (18%) each with amplification in *FGF3, FGF4*, and *FGF19*, two (12%) with *CCND1* amplification, and one with *CCNE1* amplification. *FGF 3, 4* and *19* encode various fibroblast growth factors and are known to be located a region of chromosome 11q13 that also encodes key regulators of cell-cycle progression \[[@R12]\].

Impaired epigenetic regulation and DNA methylation {#s2_5}
--------------------------------------------------

Similarly, 8 (47%) had impaired epigenetic regulation and DNA methylation with mutations in most commonly in *ARID1A* which encodes the AT-rich interactive domain-containing protein 1A, a member of the SWI/SNF chromatin remodeling complex. Three different mutations in *ARID1A* were reported (the frameshift mutation Y1211fs\*5, S1929fs\*25, and E2250fs\*28) \[[@R14], [@R15]\]. Other genes with reported aberrations included *MLL2* R4904\* (which is histone methyltransferase that is involved in the transcriptional response to progesterone signaling), *KDM6A* S466 (implicated in the epigenetic regulation of transcription), *SETD2* which encodes a histone lysine-36 methyltransferase (both G1644\* and N2071fs\*17 in the same patient), *ATRX* R840fs\*29 (which encodes a helicase protein and binds tightly to chromatin during chromosomal segregation at mitosis), and *CREBBP* S893L (which encodes proteins acting as intrinsic histone acetyltransferases and as stabilizers within the transcription complex) \[[@R16]\].

Other aberrations: Tumor suppressors and transcriptional regulators {#s2_6}
-------------------------------------------------------------------

Seven (41%) patients demonstrated one or more alterations in tumor suppressor genes while 10 (41%) patients had unique alterations in transcriptional regulators. Most commonly, five patients had 6 unique aberrations within *TP53*, specifically R273C, R248Q, R 196\*, and R248W including one patient with an adenocarcinoma who had a dual mutation within *TP53* with a relatively uncommon N-terminal missense mutation L45P and a concurrent Q38fs\*79, which is frameshift mutation leading to the truncation of the p53 protein prior to the conserved DNA-binding domain region. This patient\'s tumor demonstrated 8 mutations overall including alterations in the PI3K, MAPK pathways (mutations in *FBXW7*, *FGFR1*) with concurrent epigenetic and transcriptional deregulation, specifically *ARID1A*, *ETV1* rearrangement, *NOTCH1 APIP-NOTCH1* fusion, and *MYST3* amplification. One patient had an *MDM2* amplification while a second showed an *MDM4* amplification, both of which, when amplified, act as tumor suppressors acts to inhibit the activity of p53 \[[@R17], [@R18]\].

Concurrent mutations: Deregulation of cell cycle with PI3K pathway activation {#s2_7}
-----------------------------------------------------------------------------

Of the 17 patients, we further analyzed the incidence of concurrent mutations affecting two or more pathways and cell processes (Figure [1](#F1){ref-type="fig"}). Of the 8 patients with mutations leading to deregulation of the cell cycle, we identified 4 (50%) patients with a concurrent mutation in the PI3K cascade and one with *ERBB2* amplification, part of the epidermal growth factor receptor (EGFR) family. Similarly, of the 5 patients with mutations linked to the PI3K pathway, 4 (80%) occurred concurrently with an aberrance in cell cycle regulation (including *CDK12*, *CCNE1* amplification in 2 patients, *CDKN2A/B* loss). Furthermore, of the 8 patients with cell cycle aberrations, six (75%) had a concurrent mutations associated with epigenetic regulation and DNA methylation (including mutations in *KDM6A*, *MLL2*, *ARID1A* in 2 patients, and *SETD2*). Outcomes of molecular profiling for each patient are detailed in Table [4](#T4){ref-type="table"}.

![Areas of dysregulation identified on molecular profiling of CUP.](oncoscience-04-0047-g001){#F1}

###### Molecular profile outcomes for all CUP patients

  Patient   Age at diagnosis (years)   No. of prior systemic therapies   Histology        No. of mutants   Specific mutations and aberrations identified   
  --------- -------------------------- --------------------------------- ---------------- ---------------- ----------------------------------------------- ----------------------------
  1         21.0                       2                                 Epithelioid      1                EWSR1-ATF1 fusion                               
  2         59.0                       2                                 Squamous cell    6                PIK3CA H1047R                                   KDM6A S466\*
                                                                                                           ALK L560F                                       CDC73 Q333\*
                                                                                                           SOX2 amplification                              CDK12 Q570\*
  3         17.9                       2                                 Neuroendocrine   7                CCND1 amplification                             FGF19 amplification
                                                                                                           MYCL1 amplification                             FGF3 amplification
                                                                                                           MDM4 amplification                              FGF4 amplification
                                                                                                           MLL2 R4904\*                                    
  4         21.2                       3                                 Neuroendocrine   0                N/A                                             
  5         33.8                       1                                 Adenocarcinoma   8                FBXW7 splice 726+1 G\>A                         APIP-NOTCH1 fusion
                                                                                                           FGFR1 amplification                             TP53 L45P, Q38fs\*79
                                                                                                           ARID1A Y1211fs\*5                               MYST3 amplification
                                                                                                           ETV1 rearrangement                              
  6         49.4                       5                                 Squamous cell    0                N/A                                             
  7         70.2                       8                                 Carcinoma        4                FBXW7 R465H                                     CCNE1 amplification
                                                                                                           PIK3CA Q75E                                     TP53 R273C
  8         72.0                       6                                 Carcinoma        2                FBXW7 W244\*                                    TP53 R248Q
  9         49.2                       2                                 Carcinoma        8                PIK3CA E545K & amplification                    FGFR1 amplification
                                                                                                                                                           SOX2 amplification
                                                                                                           KRAS amplification                              TP53 R196\*
                                                                                                           CCND1 amplification                             CDKN2A/B loss
  10        44.0                       3                                 Carcinoma        1                CTNNB1 S33P                                     
  11        72.4                       3                                 Adenocarcinoma   2                SMARCB1 I365fs\*22+                             SETD2 G1644\*, N2071fs\*17
  12        24.7                       0                                 Sarcomatoid      1                EWSR1-CREB1 fusion                              
  13        65.0                       3                                 Epithelioid      2                EWSR1-NR4A3 fusion                              ATRX R840fs\*29
  14        56.5                       2                                 Squamous cell    7                BRCA2 W1692fs\*3                                ARID1A S1929fs\*25
                                                                                                           CDKN2A/B loss                                   EMSY amplification
                                                                                                           MDM2 amplification                              SMAD4 P130S
                                                                                                           SOX2 amplification                              
  15        63.8                       7                                 Adenocarcinoma   5                ERBB2 amplification                             TP53 R248W
                                                                                                           CDKN2A/B loss                                   CREBBP S893L
                                                                                                           MCL1 amplification                              
  16        71.7                       8                                 Adenocarcinoma   3                FGFR3 R399C                                     NFE2L2 D11Y
                                                                                                           ARID1A E2250fs\*28                              
  17        48.0                       1                                 Carcinoma        2                NF2 splice site 448-1G\>A                       

Clinical outcomes {#s2_8}
-----------------

Of the 17 patients, 11 (65%) elected to participate in a phase I clinical trial after having met all eligibility criteria. The remaining 6 proceeded to receive conventional chemotherapies or a clinical trial closer to home. Table [5](#T5){ref-type="table"} details the specific clinical trials and outcomes of each patient in our study. One patient received monotherapy while the remaining 10 received a combination of 2 or more drugs. All 11 patients were treated with a regimen that included a targeted therapy agent. Of the 11 patients treated on phase I clinical trials, over half (n=7, 64%) received a therapy matched with their mutational profile. The best tumor responses noted were stable disease lasting 4 or more months seen in 4 patients, 3 of whom had therapy matched to their mutational profile. Two of the 11 treated patients currently remain on therapy for over 8 months, first on a combination of carboplatin, bevacizumab, and temsirolimus and the second on crizotinib and pazopanib.

###### Clinical outcomes of CUP patients treatment on a phase I therapy

  Pt \#   Age/Sex   Phase I Regimen                                      Therapy matched to molecular aberration   Best Response per RECIST                                              Phase I PFS (m)
  ------- --------- ---------------------------------------------------- ----------------------------------------- --------------------------------------------------------------------- -----------------
  1       22/M      Not treated\*                                        \-                                        \-                                                                    \-
  2       60/F      A novel PI3K inhibitor                               Yes                                       SD                                                                    5.9
  3       21/M      Vandetanib + everolimus                              No                                        PD overall (SD of target lesions, but developed a new liver lesion)   2.0
  4       25/F      Not treated\*                                        \-                                        \-                                                                    \-
  5       36/F      Carboplatin + bevacizumab + temsirolimus             Yes                                       SD (On study)                                                         8.0+
  6       54/M      Not treated\*                                        \-                                        \-                                                                    \-
  7       75/F      Everolimus + anastrozole                             Yes                                       PD                                                                    3.3
  8       74/M      Sirolimus + hydroxychloroquine                       Yes                                       SD                                                                    4.5
  9       50/M      Lenalidomide + temsirolimus                          Yes                                       PD                                                                    1.4
  10      51/F      Not treated\*                                        \-                                        \-                                                                    \-
  11      73/M      Not treated\*                                        \-                                        \-                                                                    \-
  12      28/F      Crizotinib + pazopanib                               No                                        SD (On study)                                                         8.9+
  13      67/F      Vandetanib + everolimus                              No                                        PD                                                                    2.7
  14      57/F      Liposomal doxorubicin + bevacizumab + temsirolimus   Yes                                       PD overall (SD of lung lesions, PD of liver lesion)                   2.8
  15      65/M      Not treated\*                                        \-                                        \-                                                                    \-
  16      74/M      Everolimus + denosumab                               No                                        PD                                                                    1.5
  17      48/M      Lapatinib + sirolimus                                Yes                                       PD (mixed response)                                                   1.7

\* Not treated on a phase I trial due to decision to pursue alternate therapies.

Abbreviations: PD progressive disease, PI3K phosphatidylinositol 3-kinase, PFS progression free survival, RECIST Response Evaluation Criteria In Solid Tumors, SD stable disease.

DISCUSSION {#s3}
==========

Our exploratory analysis provides insight into the molecular fingerprint of advanced, relapsed carcinoma of unknown primary. Indeed, no two patients had an identical molecular profile, highlighting the need for truly personalized therapy for this patient population with few effective therapeutic options particularly in the relapsed setting.

The role for molecular profiling to identify the tissue of origin has been explored in depth in CUP; however data into identification of somatic alterations as identifiers of tissue of origin continues to be slowly developed where coexistence patterns in concurrent mutations may suggest the organ system origin. Existing large scale molecular profiling analysis notes that *PIK3CA* H1047R and *KRAS* mutations appear to coexist in genitourinary cancers and breast cancers when noted, and are less prevalent concurrently in colorectal cancer \[[@R19]\].

Our early analysis suggests emerging patterns of aberrations where impaired cell cycle arrest has been observed concurrently with either epigenetic deregulation or activation of the cell signaling. Aberrations in signal transduction pathways including the PI3K and MAPK pathways were consistently observed. Specific mutations including *FBXW7* have been implicated in the activation of *PI3K/Akt/mTOR* signaling pathways. This mutation has been identified in a variety of solid tumors including colorectal cancer (14%), squamous cell cancer of head and neck (11%), liver (8%), and ovarian cancers (3%) \[[@R20]\]. These *FBXW7* mutations have been showed to occur prior to the F-box domain and the highly conserved WD40 repeat region, an area targeted by proteasome-mediated degradation processes. Therefore, mutations in this region have implicated in the stabilization of oncogenic intermediates including the mTOR signaling protein. Early preclinical data has revealed response to the mTOR inhibitor rapamycin in cell lines with the inactivation of Fbxw7 and confers sensitivity to rapamycin, an mTOR inhibitor, suggesting a potential role for the more widely used mTOR inhibitors temsirolimus and everolimus; however their sensitivities to rapalogs remain to be studied prospectively as retrospective reviews of patient outcomes have not shown a definitive signal of activity \[[@R20], [@R21]\]. Furthermore, early data also suggests that inactivation of Fbxw7 may confer a resistance to anti-tubulin chemotherapies \[[@R22]\]. Similarly patients harboring deregulation of the PI3K pathway through *PIK3CA* mutations including H1047R have been shown to have a response rate (defined as stable disease ≥6 months or partial response) of 45% in patients with all advanced cancers when treated with a PI3K pathway inhibitor (including mTOR inhibitors) \[[@R19]\].

Our analysis also highlights the emerging description of epigenetic deregulation in advanced CUP patients. In a subset of patients, the identification of somatic mutations in epigenetic genes encoding proteins which lead to alterations in specific DNA methylation and chromatin modification patterns, most commonly through inappropriate gene silencing \[[@R23], [@R24]\]. The increased prevalence of somatic mutations noted in CUP patients that lead to epigenetic changes reinforces the role for studying classes of drugs, specifically the histone deacetylase inhibitors such as vorinostat and panobinostat in this patient population, particularly in combination.

Furthermore, the observation of concurrent mutations further hopes to identify combinatorial strategies for this malignancy. In our set of patients, 4 of 5 (80%) patients with a *PIK3CA* mutation had a concurrent aberrance in cell cycle regulation. While 6 of 8 (75%) patients with a cell cycle aberration had a coexisting mutation associated with epigenetic regulation and DNA methylation, highlighting two potential combinations to be explored with therapeutic intent. Additionally histology-specific subset analysis reveals early insight into pathways specifically deregulated in our larger subset of patients, specifically the patient with poorly differentiated carcinoma and adenocarcinoma. In the carcinoma subset, 4 of five patients demonstrated an aberration leading to activation of the PI3K/AKT/mTOR pathway, suggesting that activation of this cascade was more closely associated with this histologic subset when compared to the other 4 subsets. In deed all 4 samples of adenocarcinoma, which was the second most predominant subtype among our CUP patients, demonstrated an aberration implicated in epigenetic deregulation.

Our preliminary analysis highlights areas of future study but also does raise limitations. Clinical outcomes have yet to be explored longitudinally, particularly given that efforts were made to match each patient to a clinical trial with evidence of target inhibition based on their mutation profi However the primary limitations of this effort were availability of specifi clinical trials at time of patient need as well as time and travel commitments to meet the clinical trial participation requirements. Moreover, there exists a selection bias and its associated implications on tumor biology given that the molecular profi was completed only on patients who were well enough to be considered for a referral to a phase I clinical trial, leading to a small sample size with tumor histologic heterogeneity. Nonetheless, these early patterns reveal cellular processes that are deregulated concurrent with signaling mechanisms and epigenetic modulations and represent novel combination therapies to be pursued in preclinical models and ultimately early phase clinical trials.

MATERIALS AND METHODS {#s4}
=====================

Patient selection and treatment {#s4_1}
-------------------------------

We identified consecutive patients with CUP referred to the Clinical Center for Targeted Therapy (Phase I Clinical Trials Program) at MD Anderson Cancer Center starting from January 1, 2011 to December 31, 2013. Eligibility criteria for participation in phase I clinical trials included age \>18 years, presence of metastatic or unresectable disease, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.0, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1, and a life expectancy \>3 months. Premenopausal women were required to have a negative pregnancy test and patients of childbearing potential to use contraception. Further eligibility criteria varied according to the particular study and all patients gave informed consent. All clinical trials were approved by the MD Anderson Institutional Review Board. Descriptive statistics summarized the patients\' characteristics.

Pathologic evaluation and mutational analyses and detection {#s4_2}
-----------------------------------------------------------

Original hematoxylin and eosin slides were reviewed by an institutional pathologist to confirm CUP. Additional immunohistochemical staining to assist in the identification of tissue of origin was conducted as per pathologist\'s discretion. Archival formalin-fixed paraffin-embedded (FFPE) slides were then obtained and cut into 10 separate 5-mm sections. Next-generation sequencing from FFPE sections was completed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory using the Illumina HiSeq2000 platform (Foundation Medicine, Cambridge, MA, USA). Over 3230 exons of 236 cancer-related genes, plus over 47 introns from 19 genes often rearranged in cancer were fully sequenced for point mutations, insertions/deletions, copy number alterations (CNAs), select gene fusions, and variants of unknown significance. Then, the aberrations were classified into 10 encompassing categories based on the pathway or cellular processes where they have been implicated, i.e. aberrations that affect apoptosis, cell cycle regulation, epigenetic modulation/DNA methylation, signal transduction mechanism (PI3K, MAPK, Wnt or a receptor tyrosine kinase\[RTK\]), transcription regulation, or tumor suppressor.
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